Hi!

When we launched our discipline-specific roundtables, the goal was simple: create space for deeper conversations within the specialized areas that make up our broader communications world. IR is one of those areas where the challenges are distinct, and where learning from peers at different stages can be genuinely helpful.

The first program that our stellar IR Roundtable is hosting will get into the reality that IR doesn't look the same across market caps, and neither does the relationship between communications and IR as companies evolve.

One Size Doesn't Fit All: IR Across Market Caps

🗓️ Tuesday, October 14th @ 12-1 p.m. ET

👉 Reserve your spot now (exclusive to T2B Pro and Student members)

Meet the panelists:

🌟 David Connolly, VP, Investor Relations and Corporate Communications, Rhythm Pharmaceuticals, and T2B IR Roundtable Member (Moderator)

🌟 Susie Lisa, SVP, Investor Relations, Vertex Pharmaceuticals

🌟 Jen Robinson, Formerly SVP, Investor Relations and Corporate Communications, Verve Therapeutics (acquired by Lilly)

We'll dig into:

• How the IR-communications partnership shifts as companies grow and when it makes sense to expand these teams
• Managing competing priorities: near-term performance vs. long-term strategy, buy-side vs. sell-side, etc.
• What actually works when preparing executives for investor conversations (and what doesn't)
• When transparency matters most and how honest communication builds trust during tough moments

Whether you're deep in IR or partner closely with your IR colleagues, this is a chance to get a candid take from folks navigating these decisions in real time.

Hope to see you there,

Lynnea

P.S. - Our next press panel, brought to us by T2B's Media Minds Roundtable, is this Friday: Hype vs. Health – A journalist's lens on emerging healthcare trends at HLTH 2025. Grab your spot if you haven't already!

​
​

​